Clinical Trial Update: A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing AL2846 capsules to placebo in advanced radioiodine-refractory differentiated thyroid carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Radioiodine-refractory Differentiated Thyroid Carcinoma

Drugs mentioned

• AL2846

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Thyroid Cancer | Phase 3 | Status: RECRUITING